Zambia received its initial consignment of Lenacapavir, an HIV prevention medicine funded by the United States, on September 1, 2026. This significant development marks a key moment in the nation's ongoing battle against HIV. The Government of Zambia took delivery of the first stock of the twice-yearly injectable pre-exposure prophylaxis (PrEP) medication at the University Teaching Hospital in Lusaka. This specialized facility served as the central point for the reception of this key pharmaceutical shipment. The official reception of the shipment was overseen by key dignitaries, including George Sinyangwe, the Ministry of Health’s Permanent Secretary for Donor Coordination, and Frank Garcia, the US Assistant Secretary of State for African Affairs. Their presence showed the collaborative nature of this initiative and the high-level commitment from both Zambia and the United States. The rollout of Lenacapavir offers Zambia an unprecedented opportunity to accelerate its prevention efforts and to protect the substantial gains made in its national HIV response over recent years.
New Prevention Tool Arrives
Lenacapavir has demonstrated remarkable efficacy, having been found to be almost 100% effective in preventing HIV infection, offering a significant advancement in prophylactic options available globally. This level of effectiveness represents a major breakthrough in the field of HIV prevention, providing a powerful new tool for individuals at risk. This new medication is part of a broader partnership effort, which prominently includes the US President’s Emergency Plan for AIDS Relief (PEPFAR). PEPFAR's involvement notes the extensive international collaboration aimed at combating the global HIV epidemic. The collaborative initiative aims not only to introduce new medications but also to enhance existing HIV prevention strategies in various nations, particularly those with high burdens of infection. The introduction of a twice-yearly injectable PrEP offers a long-acting option that can significantly improve adherence and convenience compared to daily oral regimens, thereby increasing its potential impact.
With this delivery, Zambia joins a select group of countries in Sub-Saharan Africa that have begun receiving Lenacapavir. This regional expansion signifies a concerted effort to scale up access to innovative prevention methods across the continent. Eswatini, Nigeria, Kenya, Zimbabwe, and South Africa are also part of this initial rollout, indicating a coordinated regional approach to HIV prevention. The introduction of Lenacapavir in these countries represents a key step in broadening the scope of HIV prevention and control measures. This collective action is designed to maximize the impact of this highly effective medication, reaching more individuals and communities vulnerable to HIV infection. The long-acting nature of Lenacapavir is expected to be particularly beneficial in settings where daily pill-taking may be challenging due to various socio-economic or logistical factors.
Addressing Zambia's HIV Burden
Zambia recorded a concerning 23,000 new HIV infections in 2025, showing the ongoing public health challenge the country faces despite significant prevention and treatment efforts. These figures highlight the persistent need for innovative and highly effective prevention strategies. A significant portion of these new cases affected younger demographics, with adolescents and young people accounting for 37% of all new annual HIV infections in 2025. This disproportionate impact on youth emphasizes the urgency of tailored interventions for this age group. Within this vulnerable group, adolescent girls and young women were particularly impacted, representing 29% of the total new annual infections during the same year. These statistics highlight the specific vulnerabilities and challenges faced by younger populations, especially females, in acquiring HIV in Zambia. The introduction of Lenacapavir is therefore seen as a critical intervention to protect these at-risk groups.
Beyond new infections, vertical transmission of HIV from mother to child remains a concern, with an estimated rate of around 6% in Zambia. This figure, though reduced from previous years, still represents a significant challenge in achieving an HIV-free generation. The country's HIV burden is part of a broader regional context, as Sub-Saharan Africa continues to bear the brunt of the global HIV epidemic. This region accounts for the highest number of people living with HIV worldwide, with an alarming 26.3 million individuals out of a global total of 41 million. This widespread regional prevalence emphasizes the critical need for effective prevention and treatment strategies not only in Zambia but also across the entirety of Sub-Saharan Africa. The availability of a highly effective, long-acting PrEP like Lenacapavir is therefore a beacon of hope for reducing transmission rates and improving public health outcomes across the region.
Ambitious Rollout Targets
UNAIDS is partnering with the Zambian government, communities, the Global Fund to Fight AIDS, TB and Malaria, and the US government to facilitate the full rollout of Lenacapavir. This collaborative effort aims to ensure widespread distribution and uptake of the new HIV prevention medication across the country. UNAIDS has set an ambitious target to reach 82,000 individuals with Lenacapavir by the end of 2026. This target demonstrates a clear commitment to rapidly scale up access to this new prevention tool. The program intends to achieve this through an extensive network of 542 health facilities across Zambia, signifying a broad geographical reach for the prevention initiative to maximize its impact. Among the targeted beneficiaries, approximately 21,000 are pregnant and breastfeeding women, noting a specific focus on protecting this particularly vulnerable population and preventing vertical transmission of HIV. This strategic targeting shows the multi-faceted approach being taken to address the various dimensions of the HIV epidemic in Zambia.
